Research findings reveal that EGFR-TKIs lead to an increase in TROP2 levels in DTP cells, supporting the combination of sac-TMT with EGFR-TKI. The Company is currently in the process of conducting a Phase III registrational trial for sac-TMT in conjunction with osimertinib for the initial treatment of advanced EGFR-mutant NSCLC. This trial marks a crucial step in evaluating the efficacy and safety of this combination therapy, as well as its potential impact on patient outcomes. The study aims to provide valuable insights and data on the effectiveness of this treatment approach in a real-world clinical setting.